Axl kinase as a key target for oncology: Focus on small molecule inhibitors

Molecular Cancer Therapeutics

Volumn 13, Issue 9, 2014, Pages 2141-2148

  Feneyrolles, Clémence ^a   Spenlinhauer, Aurélia ^a   Guiet, Léa ^a   Fauvel, Bénédicte ^a   Daydé Cazals, Bénédicte ^a   Warnault, Pierre ^a   Chevé, Gwénaël ^a   Yasri, Aziz ^a  

^a OriBase Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXL RECEPTOR TYROSINE KINASE; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; GENE EXPRESSION REGULATION; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASMS; ONCOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84907220421     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-1083     Document Type: Review

References (77)

1. Liu E, Hjelle B, Bishop JM. Transforming genes in chronic myelogenous leukemia. Proc Natl Acad Sci U S A 1988; 85:1952-6.
2. O'Bryan JP, Frye RA, Cogswell P.C., Neubauer A., Kitch B, Prokop C, et al. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptortyrosine kinase. Mol Cell Biol 1991; 11:5016-31.
3. Janssen JW, Schulz AS, Steenvoorden A.C., Schmidberger M., Strehl S, Ambros PF, et al. A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 1991; 6:2113-20.
4. Neubauer A, Fiebeler A, Graham D.K., O'Bryan JP, Schmidt CA, Barckow P, et al. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 1994; 84: 1931-41.
5. Nielsen-Preiss SM, Allen MP, Xu M, Linseman D.A., Pawlowski JE, Bouchard RJ, et al. Adhesion-related kinase induction of migration requires phosphatidylinositol-3-kinaseand ras stimulation of rac activity in immortalized gonadotropin-releasing hormone neuronal cells. Endocrinology 2007; 148:2806-14.
6. Paccez JD, Vogelsang M, Parker M.I., Zerbini LF. The receptortyrosine kinase Axl in cancer: Biological functions and therapeutic implications: The role of Axl in cancer. Int J Cancer 2014; 134:1024-33.
7. Varnum BC, Young C, Elliott G., Garcia A, Bartley TD, Fridell YW, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 1995; 373: 623-6.
8. Linger RMA, Keating AK, Earp H.S., Graham DK. TAM receptortyrosine kinases: biologic functions, signaling, and potential therapeutic targetng in human cancer. Adv Cancer Res 2008; 100:35-83
9. Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Gohring W, Ullrich A, et al. Structural basis for Gas6-Axl signalling. EMBO J 2006; 25:80-7.
10. Ruan GX, Kazlauskas A. Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J 2012; 31:1692-703.
11. Braunger J, Schleithoff L, Schulz A.S., Kessler H., Lammers R, Ullrich A, et al. Intracellular signaling of the Ufo/Axl receptortyrosine kinase is mediated mainly by a multi-substrate docking-site. Oncogene 1997; 14:2619-31.
12. Ling L, Templeton D, Kung HJ. Identification of the major autopho-sphorylation sites of Nyk/Mer, an NCAM-related receptor tyrosine kinase. J Biol Chem 1996; 271:18355-62.
13. Burchert A, Attar EC, McCloskey P, Fridell Y.W., Liu ET. Determinants for transformation induced by the Axl receptortyrosine kinase. Oncogene 1998; 16:3177-87.
14. Fridell YW, Jin Y, Quilliam L.A., Burchert A., McCloskey P, Spizz G, et al. Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol 1996; 16: 135-45.
15. Stenhoff J, Dahlbäck B, Hafizi S. Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts. Biochem Biophys Res Commun 2004; 319:871-8.
16. Goruppi S, Ruaro E, Varnum B., Schneider C. Requirement of phos-phatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts. Mol Cell Biol 1997; 17:4442-53.
17. Hasanbasic I, Cuerquis J, Varnum B., Blostein MD. Intracellular signaling pathways involved in Gas6-Axl-mediated survival of endothelial cells. Am J Physiol Heart Circ Physiol 2004; 287:H1207-1213.
18. Bellosta P, Costa M, Lin D.A., Basilico C. The receptortyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol 1995; 15:614-25.
19. Suleiman L, Négrier C, Boukerche H. Protein S: a multifunctional anticoagulant vitamin K-dependent protein at the crossroads of coagulation, inflammation, angiogenesis, and cancer. Crit Rev Oncol Hematol 2013; 88:637-54.
20. Hafizi S, Alindri F, Karlsson R., Dahlbäck B. Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-containing protein with homology to tensin. Biochem Biophys Res Commun 2002; 299: 793-800.
21. Hafizi S, Ibraimi F, Dahlbäck B. C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration. FASEB J 2005; 19:971-3.
22. Kamata H, Hirata H. Redox regulation of cellular signalling. Cell Signal 1999; 11:1-14.
23. Konishi A, Aizawa T, Mohan A., Korshunov VA, Berk BC. Hydrogen peroxide activates the Gas6-Axl pathway in vascular smooth muscle cells. J Biol Chem 2004; 279:28766-70.
24. Valverde P. Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and downregulation. Biochem Biophys Res Commun 2005; 333: 180-5
25. Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 2011; 10: 1763-73.
26. Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A 2010; 107:1124-9.
27. Koorstra JBM, Karikari CA, Feldmann G, Bisht S., Rojas PL, Offerhaus GJA, et al. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 2009; 8:618-26.
28. Tai KY, Shieh YS, Lee C.S., Shiah SG, Wu CW. Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene 2008; 27:4044-55.
29. Paccez JD, Vasques GJ, Correa RG, Vasconcellos JF, Duncan K, Gu X, et al. The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene 2013; 32:689-98.
30. Li Y, Ye X, Tan C., Hongo JA, Zha J, Liu J, et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 2009; 28:3442-55.
31. Dunne PD, McArt DG, Blayney JK, Kalimutho M, Greer S, Wang T, et al. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin Cancer Res 2014; 20:164-75.
32. Song X, Wang H, Logsdon C.D., Rashid A., Fleming JB, Abbruzzese JL, et al. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 2011; 117:734-43.
33. Mahadevan D, Cooke L, Riley C., Swart R, Simons B, Della Croce K, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007; 26: 3909-19.
34. Zhang Z, Lee JC, Lin L, Olivas V., Au V, LaFramboise T, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012; 44:852-60.
35. Giles KM, Kalinowski FC, Candy P.A., Epis MR, Zhang PM, Redfern AD, et al. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther 2013; 12:2541-58.
36. Liu L, Greger J, Shi H., Liu Y, Greshock J, Annan R., et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009; 69:6871-8
37. Huang X, Finerty P Jr, Walker JR, Butler-Cole C, Vedadi M, Schapira M, et al. Structural insights into the inhibited states of the Mer receptor tyrosine kinase. J Struct Biol 2009; 165:88-96.
38. Porter J, Lumb S, Franklin R.J., Gascon-Simorte JM, Calmiano M, Riche K.L., et al. Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett 2009; 19:2780-4.
39. Favelyukis S, Till JH, Hubbard S.R., Miller WT. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 2001; 8:1058-63.
40. Mollard A, Warner SL, Call L.T., Wade ML, Bearss JJ, Verma A, et al. Design, synthesis and biological evaluation of a series of novel Axl kinase inhibitors. ACS Med Chem Lett 2011; 2:907-12.
41. Metz JT, Johnson EF, Soni NB, Merta PJ, Kifle L, Hajduk PJ. Navigating the kinome. Nat Chem Biol 2011; 7:200-2.
42. Godden JW, Bajorath J. An information-theoretic approach to descriptor selection for database profiling and QSAR modeling. QSAR Comb Sci 2003; 22:487-97.
43. Paolini GV, Shapland RHB, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat Biotechnol 2006; 24: 805-15.
44. Bamborough P, Drewry D, Harper G., Smith GK, Schneider K. Assessment of chemical coverage of kinome space and its mplications for kinase drug discovery. J Med Chem 2008; 51: 7898-914.
45. Suàrez RM, Chevot F, Cavagnino A., Saettel N, Radvanyi F, Piguel S., et al. Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. Eur J Med Chem 2013; 61:2-25.
46. Rho JK, Choi YJ, Kim S.Y., Kim TW, Choi EK, Yoon SJ, et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to to EGFR kinase inhibitors due to MET or AXL activation. Cancer Res 2014; 74:253-62.
47. Trask PC, Cella D, Besson N., Kelly V, Masszi T, Kim DW. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res 2012; 36:438-42.
48. Khoury HJ, Cortes JE, Kantarjian H.M., Gambacorti-Passerini C, Bac-carani M, Kim D-W, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012; 119:3403-12.
49. Levinson NM, Boxer SG. Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PloS ONE 2012; 7:e29828.
50. Boschelli F, Arndt K, Gambacorti-Passerini C. Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia. Eur J Cancer 2010; 46:1781-9.
51. Nagilla M, Brown RL, Cohen EEW. Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv Ther 2012; 29:925-34.
52. Hart CD, De Boer RH. Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. OncoTargets Ther 2013; 6:1-7.
53. Yakes FM, Chen J, Tan J., Yamaguchi K, Shi Y, Yu P., et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10:2298-308.
54. Kitagawa D, Yokota K, Gouda M., Narumi Y, Ohmoto H, Nishiwaki E., et al. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells 2013; 18:110-22.
55. Qian F, Engst S, Yamaguchi K., Yu P, Won KA, Mock L, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009; 69:8009-16.
56. LifeSciAdvisors. Mirai Therapeutics [Initation report]. Available from: http://lifesciadvisors.com/clients/mirati/ [accessed November 15, 2013]. 2013 Jul. p. 51.
57. Gherardi E, Birchmeier W, Birchmeier C., Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12: 89-103.
58. Schroeder GM, An Y, Cai ZW, Chen XT, Clark C, Cornelius LAM, et al. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1, 2-dihydropyridine-3-carboxa-mide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem 2009; 52:1251-4.
59. Yan SB, Peek VL, Ajamie R, Buchanan SG, Graff JR, Heidler SA, et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs 2013; 31:833-44.
60. Burbridge MF, Bossard CJ, Saunier C, Fejes I., Bruno A, Léonce S, et al. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol Cancer Ther 2013; 12:1749-62.
61. Holland SJ, Pan A, Franci C., Hu Y, Chang B, Li W., et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 2010; 70:1544-54.
62. Tolero Pharmaceuticals, Inc-TP-0903 [Internet]. 2013 [cited 2013 May 7]. Available from: http://www.toleropharmaceuticals.com/TP-0903.html.
63. Byers LA, Diao L, Wang J., Saintigny P, Girard L, Peyton M., et al. An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013; 19:279-90.
64. Astex Pharmaceuticals. Astex pharmaceuticals discontinues amuva-tinib clinical development program [Internet]. 2012 [cited 2013 Nov 18]. Available from: http://investor.astx.com/releasedetail.cfm?ReleaseID=708646.
65. Oslob JD, Romanowski MJ, Allen D.A., Baskaran S., Bui M, Elling RA, et al. Discovery of a potent and selective aurora kinase inhibitor. Bioorg Med Chem Lett 2008; 18:4880-4.
66. Sunesis Pharmaceuticals Inc - Form 10-K-March 31, 2010 [Internet]. getfilings.com; 2013. Available from: http://www.getfilings.com/sec-filings/100331/SUNESIS-PHARMACEUTICALS-INC-10-K/.
67. Hubbard SR, Wei L, Ellis L., Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994; 372:746-54.
68. Hubbard SR. Crystal structure of the activated insulin receptortyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 1997; 16:5572-81.
69. Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev 2001; 81:999-1030.
70. Angelillo-Scherrer A, Burnier L, Flores N, Savi P, DeMol M, Schaeffer P, et al. Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest 2005; 115:237-46.
71. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol 2008; 8:327-36.
72. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 2010; 29:5254-64.
73. Cerchia L, Esposito CL, Camorani S, Rienzo A., Stasio L, Insabato L, et al. Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther J Am Soc Gene Ther 2012; 20:2291-303.
74. Remsing Rix LL, Rix U, Colinge J., Hantschel O, Bennett KL, Stranzl T, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009; 23:477-85.
75. Davis MI, Hunt JP, Herrgard S, Ciceri P., Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29:1046-51.
76. You WK, Sennino B, Williamson C.W., Falcon B., Hashizume H, Yao LC, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 2011; 71:4758-68.
77. Shi H, Liu L, Greger J., Gilmer T. Abstract #1746: GSK1363089 inhibits MET and synergizes with HER targeted agents in MET amplified/over-expressed and HER1/HER2 amplified tumor cells. AACR Meet Abstr 2009; 2009:1746.